The Board of UDG Healthcare plc (the 'Company') is pleased to announce the appointment of Mr Myles Lee as a non-executive director of the Company with effect from 1 April 2017.
Myles was Group Chief Executive of CRH plc, a FTSE100 and Fortune 500 company, prior to retiring in December 2013. With more than thirty years’ experience at senior financial and managerial level, Myles has extensive global experience in management, M&A and finance. He is a qualified civil engineer and a Fellow of the Institute of Chartered Accountants in Ireland.
Myles also currently serves on the Board of Ingersoll Rand Inc, a Fortune 500 company and Babcock International Group plc, a FTSE100 company.
Commenting on the appointment, Chairman Peter Gray said "We are delighted that Myles has agreed to join the Board. His intimate involvement in helping build CRH, a global company which became a world leader through organic and acquisitive growth, will bring great experience to UDG as we continue to build our business.”
There is no further information to be disclosed pursuant to Listing Rule 9.6.13.
General Counsel & Company Secretary
Deputy Company Secretary
Lisa Kavanagh / Jack Hickey
Tel: +44-207-250-1446 / email@example.com
About UDG Healthcare plc:
UDG Healthcare plc (LON: UDG) is a leading international partner of choice delivering commercial, clinical, communications and packaging services to the healthcare industry, employing almost 8,000 people with operations in 23 countries and delivering services in over 50 countries.
UDG Healthcare plc operates across three divisions: Ashfield, Sharp and Aquilant.
Ashfield is a global leader in commercialisation services for the pharmaceutical and healthcare industry, operating across two broad areas of activity: commercial & clinical services, and communications services. It focuses on supporting healthcare professionals and patients at all stages of the product life cycle. The division provides field and contact centre sales teams, healthcare communications, patient support, audit, advisory, medical information and event management services to over 300 healthcare companies.
Sharp is a global leader in contract commercial packaging and clinical trial packaging services for the pharmaceutical and biotechnology industries, operating from state of the art facilities across the US and Europe. Sharp is also a world leader in ’Track and Trace’ serialisation services, which will require all prescription drugs to have a unique serial code for authentication and traceability.
Aquilant is a leading provider of outsourced sales, marketing, distribution and engineering services to the medical and scientific sectors in the UK, Ireland and the Netherlands.
The company is listed on the London Stock Exchange and is a constituent of the FTSE 250.
For more information, please go to: www.udghealthcare.com